Status: Recruiting
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Participants needed: 312
Trial details
Phase: Phase 3Age: 19-65Biological sex: AllType: InterventionalSponsor: Huons BiopharmaUpdated: Oct 3, 2024Locations: 1
Eligibility criteria
19 Years to 65 Years(Adult, Older Adult) [+2]
Subject who has history of any diseases following. (myasthenia gravis, Eaton-Lam... [+18]